New pill aims to stop dangerous platelet drop in breast cancer treatment
NCT ID NCT07198672
First seen Nov 01, 2025 · Last updated May 17, 2026 · Updated 27 times
Summary
This study tests whether the drug herombopag can prevent low platelet counts (thrombocytopenia) in people with HER2-positive breast cancer receiving T-DM1 therapy. Low platelets are common in Asian patients and can cause bleeding or force treatment delays. About 45 participants will take herombopag tablets alongside their regular cancer treatment to see if it keeps platelet levels safe.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HER2-POSITIVE BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.